COMMUNIQUÉS West-GlobeNewswire

IBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per Share
14/03/2024
MONTRÉAL, March 14, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) announces that it has filed an addendum to its management proxy circular dated February 23, 2024 for [...]
Bayer and Aignostics to collaborate on next generation precision oncology
14/03/2024
Not intended for UK Media Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer’s precision oncology [...]
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
14/03/2024
AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE [...]
Amolyt Pharma conclut un accord définitif visant son acquisition par AstraZeneca
14/03/2024
AstraZeneca fera l’acquisition d’Amolyt Pharma pour un total pouvant atteindre 1,05 milliard de dollars. L’opération devrait être finalisée au troisième trimestre de 2024. Lyon (France) et Cambridge, Massachusetts, 14 [...]
Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
14/03/2024
TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid [...]
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
14/03/2024
Relation Therap eutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm London, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging [...]
PanTera signs a second agreement for the supply of actinium-225
14/03/2024
PanTera’s continues to deploy its strategy to become a market leader into the production and distribution of Ac225 Mol, Belgium, March 14, 2024: PanTera, the Belgian radioisotope producer created as a joint venture by [...]
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
14/03/2024
Enabling Technology Supports the Development of Anocca’s Deep Pipeline of TCR-T therapeutics NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T [...]
Addex to Present at the Bio-Europe Spring 2024 Conference
14/03/2024
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, [...]
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
14/03/2024
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in [...]
Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives
14/03/2024
Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives Le total des produits et autres revenus atteint 4,4 millions d’euros Forte croissance du chiffre d’affaires et de la marge bute attendue en 2024, [...]
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
14/03/2024
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 million Stronger growth expected in 2024 of both sales and gross margin, mainly fueled by the [...]
Pharming Group reports fourth quarter and full year 2023 financial results
14/03/2024
Full year 2023 total revenues increased by 19% to US$245.3 million Record fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 million Strong [...]
Communication at the request of the FSMA on the transactions with Qliniq
14/03/2024
Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 (HY 2023) financial statements following a correction of a non-cash error in the accounting treatment of [...]
Communiqué à la requête de la FSMA sur les transactions avec QliniQ
14/03/2024
Communiqué à la requête de la FSMA sur les transactions avec QliniQ Retraitement des états financiers de 2022 et de juin 2023 suite à une correction d’une erreur dans le traitement comptable des transactions réalisées [...]
Antheia et Olon poursuivent leur partenariat pour la biofabrication de matières premières essentielles et de principes actifs pharmaceutiques d'Antheia pour les médicaments essentiels
14/03/2024
Olon soutiendra la poursuite de la mise à l'échelle et de la commercialisation des produits de première génération d'Antheia MENLO PARK, Californie et MILAN, Italie, 14 mars 2024 (GLOBE NEWSWIRE) -- Antheia , le [...]
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
14/03/2024
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to [...]
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
13/03/2024
MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key [...]
New Employee Elected Directors to the Board of Zealand Pharma A/S
13/03/2024
Company announcement – No. 14 / 2024 New Employee Elected Directors to the Board of Zealand Pharma A/S Copenhagen, Denmark, March 13, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78). The [...]

Pages